Trials / Completed
CompletedNCT00439270
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib | Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression |
| DRUG | Docetaxel | Infusion, 60 or 75 mg/m\^2, administered every 3 weeks. |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2012-02-01
- Completion
- 2013-01-01
- First posted
- 2007-02-23
- Last updated
- 2014-03-28
- Results posted
- 2013-11-27
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00439270. Inclusion in this directory is not an endorsement.